GALT
Galectin Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.65
+6.83%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 8.9M | 14.3M | 36.6M | 32.1M | 31.7M |
| SG&A Expense | 6.7M | 5.8M | 5.9M | 5.9M | 6.6M |
| General & Admin Expense | 6.7M | 5.8M | 5.9M | 5.9M | 6.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 15.6M | 20.1M | 42.4M | 38.1M | 38.4M |
| Cost and Expenses | 15.6M | 20.1M | 42.4M | 38.1M | 38.4M |
| Operating Income (EBIT) | (15.6M) | (20.1M) | (42.4M) | (38.1M) | (38.4M) |
| Non-Operating | |||||
| Interest Income | 129.0K | 126.0K | 338.0K | 230.0K | 52.0K |
| Interest Expense | 7.8M | 7.3M | 5.5M | 2.8M | 1.0M |
| Net Interest Income | (7.6M) | (7.2M) | (5.2M) | (2.6M) | (981.0K) |
| Other Non-Op Income/Expense | (12.2M) | (10.8M) | (4.6M) | (3.0M) | (424.0K) |
| Non-Operating Income (excl Interest) | (1.8M) | 3.4M | (926.0K) | 202.0K | (609.0K) |
| EBT (Pre-Tax Income) | (27.8M) | (30.8M) | (47.0M) | (41.1M) | (38.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (27.8M) | (30.8M) | (47.0M) | (41.1M) | (38.8M) |
| Earnings from Cont. Ops | (27.8M) | (30.8M) | (47.0M) | (41.1M) | (38.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.9M) | (30.8M) | (47.2M) | (44.8M) | (38.9M) |
| Per Share | |||||
| Basic EPS | ($0.43) | ($0.48) | ($0.76) | ($0.74) | ($0.65) |
| Diluted EPS | ($0.43) | ($0.48) | ($0.76) | ($0.74) | ($0.65) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 65.9M | 63.9M | 62.3M | 60.2M | 59.4M |
| Diluted Shares Outstanding | 65.9M | 63.9M | 62.3M | 60.2M | 59.4M |
| Profitability Metrics | |||||
| EBITDA | (13.8M) | (23.5M) | (41.5M) | (38.2M) | (37.7M) |
| D&A | 53.0K | 53.0K | 37.0K | 33.0K | 32.0K |
| EBIT | (13.8M) | (23.5M) | (41.5M) | (38.3M) | (37.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026